Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b

Journal of Drugs in Dermatology

Volumn 9, Issue 4, 2010, Pages 381-384

  Fernández Vozmediano, José Manuel ^a   Armario Hita, José Carlos ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PARACETAMOL;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; ASYMPTOMATIC DISEASE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SIZE; DRUG FEVER; DRUG INDUCED HEADACHE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LYMPHOCYTOSIS; MALAISE; MALE; MYALGIA; NASAL PYRAMID; NERVOUSNESS; NEUTROPENIA; NOSE; SIDE EFFECT; SKIN BIOPSY; TREATMENT DURATION; INTRALESIONAL DRUG ADMINISTRATION; MIDDLE AGED; NOSE TUMOR; PATHOLOGY;

ADULT; CARCINOMA, BASAL CELL; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON ALFA-2B; MALE; MIDDLE AGED; NOSE NEOPLASMS;

EID: 77953635657     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Gresser I. Biologic effects of interferons. J Invest Dermatol. 1990;95(6 Suppl):66S-71S.
2. Conejo-Mir J, Camacho F, Gonzalez Campora R. Dermatopathological study on the mechanism of tumoral regression induced by intralesional alpha-2b IFN in basal cell carcinomas. J Cut Path. 1991;18:364.
3. Chimenti S, Peris K, Di Cristofaro S, et al. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology (Basel). 1995;190(3):214-217.
4. Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990;23(4 Pt 1):694-700. (Pubitemid 20336398)
5. Edwards L, Tucker SB, Perednia D, et al. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas. Arch Dermatol. 1990;126(8):1029-1032.
6. Greenway HT, Cornell RC, Tanner DJ, et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol. 1986;15(3):437-443. (Pubitemid 16054109)
7. Buechner SA. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol. 1991;24(5 Pt 1):731-734.
8. Boneschi V, Brambilla L, Mozzanica N, et al. Treatment of basal cell carcinomas with intralesional alpha 2b recombinant interferon [abstract]. J. Invest. Dermatol. 1989;93:542-543.
9. Mozzanica N, Cattaneo A, Boneschi V, et al. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon. Arch Dermatol Res. 1990;282(5):311-317. (Pubitemid 20229793)
10. Buechner SA, Wernli M, Harr T, et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas) - CD95 ligand-induced suicide. J Clin Invest. 1997;100(11):2691-2696. (Pubitemid 28007536)